2 Nov 2016director interest notice● Neutral
Arcadia Biosciences, Inc. director Kevin Comcowich received a stock option grant for 47,910 shares.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
2 Nov 2016director interest notice● Neutral
Kevin Comcowich became a Arcadia Biosciences, Inc. director and company insider (initial ownership filing).
12 Sept 2016director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Matthew T Plavan received a stock option grant for 500,000 shares.
12 Sept 2016director interest notice● Neutral
Matthew T Plavan became a Arcadia Biosciences, Inc. Chief Financial Officer and company insider (initial ownership filing).
12 Sept 2016director interest notice● Neutral
Matthew T Plavan became a Arcadia Biosciences, Inc. Chief Financial Officer and company insider (initial ownership filing).
22 Aug 2016director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Scientific Officer Vic C. Knauf received a stock option grant for 75,000 shares.
22 Aug 2016director interest notice● Neutral
Arcadia Biosciences, Inc. director George Frederick John Gosbee received a stock option grant for 18,112 shares.
22 Aug 2016director interest notice● Neutral
Arcadia Biosciences, Inc. VP, Chief Legal Officer Wendy S. Neal received a stock option grant for 75,000 shares.
22 Aug 2016director interest notice● Neutral
Arcadia Biosciences, Inc. director Rajiv Shah received a stock option grant for 18,112 shares.
22 Aug 2016director interest notice● Neutral
Arcadia Biosciences, Inc. director Darby E Shupp received a stock option grant for 24,149 shares.
22 Aug 2016director interest notice● Neutral
Arcadia Biosciences, Inc. VP Product Development Zhongjin Lu received a stock option grant for 50,000 shares.
22 Aug 2016director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Operating Officer Roger Salameh received a stock option grant for 75,000 shares.
22 Aug 2016director interest notice● Neutral
Arcadia Biosciences, Inc. director Uday Garg received a stock option grant for 18,112 shares.
9 Aug 2016quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.6 million for the period ended 2016-06-30.
9 Aug 2016quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.6 million for the period ended 2016-06-30.
8 Aug 2016director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Operating Officer Roger Salameh exercised stock options for 100 shares and disposed of 200 shares.
22 July 2016listing compliance notice▼ Bad
Arcadia fell out of Nasdaq compliance on board independence after two independent directors resigned, leaving the board evenly split between independent and non-independent members; the company said it planned to add a new independent director before the cure period expired.
20 July 2016director interest notice● Neutral
James Richard Reis became a Arcadia Biosciences, Inc. director and company insider (initial ownership filing).
20 July 2016director interest notice● Neutral
Matthew A. Ankrum became a Arcadia Biosciences, Inc. director and company insider (initial ownership filing).
15 June 2016director interest notice● Neutral
Arcadia Biosciences, Inc. Interim Chief Financ. Officer Steven F. Brandwein sold 8,280 shares at $2.49.
25 May 2016director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Rajendra D. Ketkar received a stock option grant for 750,000 shares.
24 May 2016director interest notice● Neutral
Rajendra Dinkar Ketkar became a Arcadia Biosciences, Inc. Chief Executive Officer and company insider (initial ownership filing).
10 May 2016quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $5.2 million for the period ended 2016-03-31.
16 Feb 2016substantial holder notice● Neutral
Mandala Agribusiness Co-Investments I Limited, Mandala Agribusiness Fund, Mandala Capital AG Ltd, Uday Garg, Dominic Redfern, Tej Gujadhur, Sheokumar Gujadhur disclosed a new substantial Arcadia Biosciences, Inc. shareholding (22.60% of votes).
30 Dec 2015debt financing▲ GoodMajor
Arcadia Biosciences refinanced its debt, borrowing $25 million from Silicon Valley Bank under a new term loan (0.90% above prime, secured by substantially all assets) and using the proceeds to fully prepay its prior Tennenbaum Capital term loan -- swapping an expensive private-credit lender for a conventional bank facility shortly after its 2015 IPO.
5 Nov 2015quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.6 million for the period ended 2015-09-30.
5 Nov 2015quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.6 million for the period ended 2015-09-30.
11 Aug 2015quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $3.7 million for the period ended 2015-06-30.
10 Aug 2015quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $3.7 million for the period ended 2015-06-30.
26 May 2015substantial holder notice● Neutral
Moral Compass Corporation, Terri Bishop, Peter Sperling, Darby Shupp, John G. Sperling disclosed a new substantial Arcadia Biosciences, Inc. shareholding (52.10% of votes).